Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Inkwood Research | PRODUCT CODE: 1294752

Cover Image

PUBLISHER: Inkwood Research | PRODUCT CODE: 1294752

Europe Skin Cancer Diagnostics Market Forecast 2023-2032

PUBLISHED:
PAGES: 156 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 1600
PDF (Corporate License)
USD 2200

Add to Cart

KEY FINDINGS

The Europe skin cancer diagnostics market is projected to register a CAGR of 6.72% during the forecast period, 2023-2032. The market growth is attributed to proactive measures, educational initiatives, and public health campaigns undertaken by individuals and healthcare providers.

MARKET INSIGHTS

Belgium, Poland, Italy, Nordic Countries, Germany, Spain, France, the United Kingdom, and Rest of Europe are assessed for the Europe skin cancer diagnostics market growth evaluation. In Italy, as per the Italian Cancer Society, new skin melanoma's annual average stands at 12.5 per 100,000 males and 13. per 100,000 females. Also, as per the World Health Organization 2020 data, skin cancer deaths reached 3239 total deaths in the country. Further, the cost of anticancer drugs is on the rise. For instance, the treatment cost of advanced melanoma range around €2972 in Italy. In addition, the pharmaceutical expense for anticancer drugs increased from 3.6 to 5 billion euros between 2013-2017.

At the same time, as per stats, the public healthcare expenditure has increased steadily in the last two decades, exceeding 127 billion euros as of 2021. Similarly, private healthcare expenditure reached almost 4 billion euros in 2020. As a result, the rising costs of anticancer drugs in Italy reflect the growing demand for effective skin cancer treatment, including skin cancer diagnostics. This offers growth opportunities for the Italy skin cancer diagnostics market.

Whereas countries like Spain have a well-developed medical technology industry, which encompasses a vast range of diagnostic tools and devices. The Spain skin cancer diagnostics market growth is propelled by the growing aging population, increasing awareness about skin cancer risks, and advancements in diagnostic technology.

COMPETITIVE INSIGHTS

Some of the major companies operating in the market include: F Hoffmann-La Roche Ltd, AMLo Biosciences Limited, NeraCare GmbH, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation caters to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • The competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Product Code: 51881

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. METHODOLOGY
  • 1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW
  • 2.3. SCOPE OF STUDY
  • 2.4. CRISIS SCENARIO ANALYSIS
  • 2.5. MAJOR MARKET FINDINGS
    • 2.5.1. INCREASING APPLICATION OF AI AND MACHINE LEARNING IN SKIN CANCER DIAGNOSIS TOOLS

3. MARKET DYNAMICS

  • 3.1. KEY DRIVERS
    • 3.1.1. INCREASING PREVALENCE OF SKIN CANCER
    • 3.1.2. GROWING AWARENESS ABOUT SKIN CANCER DIAGNOSIS & TREATMENT
    • 3.1.3. TECHNOLOGICAL ADVANCEMENTS IN SKIN CANCER DIAGNOSTIC PRODUCTS
  • 3.2. KEY RESTRAINTS
    • 3.2.1. HIGH COSTS ASSOCIATED WITH SKIN CANCER TREATMENTS
    • 3.2.2. STRINGENT REGULATORY FRAMEWORK
    • 3.2.3. LACK OF SKILLED MEDICAL PROFESSIONALS

4. KEY ANALYTICS

  • 4.1. PARENT MARKET ANALYSIS
  • 4.2. KEY MARKET TRENDS
  • 4.3. PORTER'S FIVE FORCES ANALYSIS
    • 4.3.1. BUYERS POWER
    • 4.3.2. SUPPLIERS POWER
    • 4.3.3. SUBSTITUTION
    • 4.3.4. NEW ENTRANTS
    • 4.3.5. INDUSTRY RIVALRY
  • 4.4. GROWTH PROSPECT MAPPING
  • 4.5. MARKET CONCENTRATION ANALYSIS
  • 4.6. VALUE CHAIN ANALYSIS
    • 4.6.1. RESEARCH AND DEVELOPMENT
    • 4.6.2. MANUFACTURING
    • 4.6.3. MARKETING AND SALES
    • 4.6.4. DISTRIBUTION AND LOGISTICS
    • 4.6.5. TRAINING AND SUPPORT

5. MARKET BY TYPE

  • 5.1. MELANOMA
  • 5.2. NON-MELANOMA

6. MARKET BY GENDER

  • 6.1. MALE
  • 6.2. FEMALE

7. MARKET BY SCREENING TYPE

  • 7.1. SKIN BIOPSY
  • 7.2. DERMATOSCOPY
  • 7.3. LYMPH NODE
  • 7.4. BIOPSY IMAGING TESTS
  • 7.5. BLOOD TESTS

8. GEOGRAPHICAL ANALYSIS

  • 8.1. EUROPE
    • 8.1.1. MARKET SIZE & ESTIMATES
    • 8.1.2. EUROPE SKIN CANCER DIAGNOSTICS MARKET DRIVERS
    • 8.1.3. EUROPE SKIN CANCER DIAGNOSTICS MARKET CHALLENGES
    • 8.1.4. KEY PLAYERS IN EUROPE SKIN CANCER DIAGNOSTICS MARKET
    • 8.1.5. COUNTRY ANALYSIS
      • 8.1.5.1. UNITED KINGDOM
      • 8.1.5.1.1. UNITED KINGDOM SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.1.5.2. GERMANY
      • 8.1.5.2.1. GERMANY SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.1.5.3. FRANCE
      • 8.1.5.3.1. FRANCE SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.1.5.4. ITALY
      • 8.1.5.4.1. ITALY SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.1.5.5. SPAIN
      • 8.1.5.5.1. SPAIN SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.1.5.6. NORDIC COUNTRIES
      • 8.1.5.6.1. NORDIC COUNTRIES SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.1.5.7. BELGIUM
      • 8.1.5.7.1. BELGIUM SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.1.5.8. POLAND
      • 8.1.5.8.1. POLAND SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.1.5.9. REST OF EUROPE
      • 8.1.5.9.1. REST OF EUROPE SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES

9. COMPETITIVE LANDSCAPE

  • 9.1. KEY STRATEGIC DEVELOPMENTS
    • 9.1.1. PRODUCT LAUNCHES & DEVELOPMENTS
    • 9.1.2. PARTNERSHIPS & AGREEMENTS
  • 9.2. COMPANY PROFILES
    • 9.2.1. AMLO BIOSCIENCES LIMITED
    • 9.2.2. BIOMERIEUX SA
    • 9.2.3. CASTLE BIOSCIENCES INC
    • 9.2.4. DERMLITE LLC
    • 9.2.5. DERMTECH INC.
    • 9.2.6. F. HOFFMANN-LA ROCHE LTD
    • 9.2.7. MICHELSON DIAGNOSTICS LTD
    • 9.2.8. NERACARE GMBH
    • 9.2.9. SKYLINEDX BV
    • 9.2.10. VERISKIN INC
Product Code: 51881

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - SKIN CANCER DIAGNOSTICS
  • TABLE 2: EUROPE SKIN CANCER DIAGNOSTICS MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 3: EUROPE SKIN CANCER DIAGNOSTICS MARKET, BY TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 4: EUROPE SKIN CANCER DIAGNOSTICS MARKET, BY GENDER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 5: EUROPE SKIN CANCER DIAGNOSTICS MARKET, BY GENDER, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 6: EUROPE SKIN CANCER DIAGNOSTICS MARKET, BY SCREENING TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 7: EUROPE SKIN CANCER DIAGNOSTICS MARKET, BY SCREENING TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 8: EUROPE SKIN CANCER DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 9: EUROPE SKIN CANCER DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 10: KEY PLAYERS OPERATING IN EUROPE SKIN CANCER DIAGNOSTICS MARKET
  • TABLE 11: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
  • TABLE 12: LIST OF PARTNERSHIPS & AGREEMENTS

LIST OF FIGURES

  • FIGURE 1: KEY MARKET TRENDS
  • FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 3: GROWTH PROSPECT MAPPING FOR EUROPE
  • FIGURE 4: MARKET CONCENTRATION ANALYSIS
  • FIGURE 5: VALUE CHAIN ANALYSIS
  • FIGURE 6: EUROPE SKIN CANCER DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY TYPE, IN 2022
  • FIGURE 7: EUROPE SKIN CANCER DIAGNOSTICS MARKET, BY MELANOMA, 2023-2032 (IN $ MILLION)
  • FIGURE 8: EUROPE SKIN CANCER DIAGNOSTICS MARKET, BY NON-MELANOMA, 2023-2032 (IN $ MILLION)
  • FIGURE 9: EUROPE SKIN CANCER DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY GENDER, IN 2022
  • FIGURE 10: EUROPE SKIN CANCER DIAGNOSTICS MARKET, BY MALE, 2023-2032 (IN $ MILLION)
  • FIGURE 11: EUROPE SKIN CANCER DIAGNOSTICS MARKET, BY FEMALE, 2023-2032 (IN $ MILLION)
  • FIGURE 12: EUROPE SKIN CANCER DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY SCREENING TYPE, IN 2022
  • FIGURE 13: EUROPE SKIN CANCER DIAGNOSTICS MARKET, BY SKIN BIOPSY, 2023-2032 (IN $ MILLION)
  • FIGURE 14: EUROPE SKIN CANCER DIAGNOSTICS MARKET, BY DERMATOSCOPY, 2023-2032 (IN $ MILLION)
  • FIGURE 15: EUROPE SKIN CANCER DIAGNOSTICS MARKET, BY LYMPH NODE, 2023-2032 (IN $ MILLION)
  • FIGURE 16: EUROPE SKIN CANCER DIAGNOSTICS MARKET, BY BIOPSY IMAGING TESTS, 2023-2032 (IN $ MILLION)
  • FIGURE 17: EUROPE SKIN CANCER DIAGNOSTICS MARKET, BY BLOOD TESTS, 2023-2032 (IN $ MILLION)
  • FIGURE 18: EUROPE SKIN CANCER DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)
  • FIGURE 19: UNITED KINGDOM SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 20: GERMANY SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 21: FRANCE SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 22: ITALY SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 23: SPAIN SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 24: NORDIC COUNTRIES SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 25: BELGIUM SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 26: POLAND SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 27: REST OF EUROPE SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!